Sam Fazeli

Very similar to the Pfizer CREST study and trial design, but Infinzi is used for one year

versus Sazanlimab for two years.

And Potomac showed earlier EFS curve separation that was at about three months and crest.

Do you want to just talk to us about this comparison I'm making, which is, again, not head-to-head, of course, and also what it means for the role of Mfinzine in non-muscle-invasive bladder cancer, especially patients with Sari, this particular type of it, which is carcinoma in situ.

Yeah.

So just let me move on quickly to, thank you for that.

The other data set we saw from Combo that seems to be doing very well in the setting.

So this is the non-metastatic MIBC.

This was Keynote 905.

I think it did have an EV number.

I can't remember.

And which was infortimab vedotin, which is a nectin-4 ADC that now is owned by Pfizer, plus Keytruda pembrolizumab.

Good perioperative regime.

And I think it got lots of claps, et cetera, at the conference because bladder cancer physicians haven't seen data like this in decades.

in cisplatin ineligible patients.

Now this is obviously a more frail and not necessarily the same patient population that was tested in Niagara.

But how do you, is there any way to think about these two trials, Niagara and Keynote 905 together?

What would I take away from making that?

And Susan, quickly, historically, has there been, you know, this continuous conversation about PD-L1 versus PD-1?

Historically, has there been any data that suggests PD-1, PD-L1 are different in the bladder setting?